Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.38 |
| ▸ | FASN | P49327 | 4/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | USP5 | P45974 | 1/20 | 0.36 |
| ▸ | USP14 | P54578 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457871 | 0.88 | FASN (0.40) | EGLN1FASNRORC | |
| SCHEMBL3457331 | 0.75 | ADAM10 (0.45) | KDM1ACYP11B1CYP11B2USP5USP14 | |
| SCHEMBL3457000 | 0.74 | EGLN1 (0.39) | EGLN1FASN | |
| SCHEMBL3457210 | 0.66 | CYP11B2 (0.37) | EGLN1CYP11B1CYP11B2 | |
| SCHEMBL3457601 | 0.66 | OXTR (0.38) | EGLN1FASNCYP11B1CYP11B2 | |
| SCHEMBL8650355 | 0.63 | KMT2A (0.51) | — | |
| SCHEMBL6359772 | 0.63 | NAMPT (0.42) | KDM1ACYP11B1CYP11B2 | |
| SCHEMBL3457201 | 0.62 | ADAM10 (0.44) | EGLN1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL2171943 | 0.62 | HTR6 (0.59) | CYP11B1CYP11B2 | |
| SCHEMBL22570906 | 0.62 | ALDH1A1 (0.45) | CYP11B1CYP11B2USP5USP14USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | disclosed |